Enhertu significantly improved overall survival and progression-free survival compared to Cyramza plus paclitaxel in HER2-positive metastatic GC/GEJ patients. The DESTINY-Gastric04 trial established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results